Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014', provides an overview of the Community-Acquired Bacterial Pneumonia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Community-Acquired Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community-Acquired Bacterial Pneumonia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Community-Acquired Bacterial Pneumonia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Community-Acquired Bacterial Pneumonia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Community-Acquired Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Community-Acquired Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Community-Acquired Bacterial Pneumonia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Community-Acquired Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Community-Acquired Bacterial Pneumonia Overview 7
Therapeutics Development 8
Pipeline Products for Community-Acquired Bacterial Pneumonia - Overview 8
Pipeline Products for Community-Acquired Bacterial Pneumonia - Comparative Analysis 9
Community-Acquired Bacterial Pneumonia - Therapeutics under Development by Companies 10
Community-Acquired Bacterial Pneumonia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Community-Acquired Bacterial Pneumonia - Products under Development by Companies 14
Community-Acquired Bacterial Pneumonia - Companies Involved in Therapeutics Development 15
Cubist Pharmaceuticals, Inc. 15
Furiex Pharmaceuticals, Inc. 16
Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. 17
Melinta Therapeutics, Inc 18
Nabriva Therapeutics AG 19
Tetraphase Pharmaceuticals Inc. 20
Community-Acquired Bacterial Pneumonia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
acorafloxacin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BC-3781 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DBAF-301 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
faropenem medoxomil - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
radezolid - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
solithromycin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TP-271 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TP-834 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Community-Acquired Bacterial Pneumonia - Recent Pipeline Updates 45
Community-Acquired Bacterial Pneumonia - Dormant Projects 56
Community-Acquired Bacterial Pneumonia - Discontinued Products 57
Community-Acquired Bacterial Pneumonia - Product Development Milestones 58
Featured News & Press Releases 58
Sep 25, 2014: Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial 58
Feb 20, 2014: Cempra Initiates Solithromycin Pediatric Program 58
Dec 16, 2013: Cempra Provides Update on Clinical Development of Solithromycin 59
Sep 10, 2013: Cempra to Present Data at ICAAC on Solithromycin's Activity Against a Broad Range of Pathogens Including Four Proposed or Designated by the Food and Drug Administration as Qualified Infectious Disease Pathogens Under the Generating Antibiotic Incentives Now Act 60
Sep 06, 2013: Cempra's Solithromycin Receives Qualified Infectious Disease Product Designation From the U.S. Food and Drug Administration 62
Jun 13, 2013: Cempra Provides Guidance On Phase III Clinical Program Required For Regulatory Approval Of Solithromycin For Community-Acquired Bacterial Pneumonia 62
May 28, 2013: Cempra Receives $58m Contract To Develop Antibiotic For Pediatric Use And Biodefense From BARDA 63
May 20, 2013: Cempra Presents Post-Phase II Analysis Of Solithromycin's Efficacy And Safety Results From Patients With Community Acquired Bacterial Pneumonia 64
Apr 29, 2013: Tetraphase Pharma Announces Presentation Of Data On Preclinical Candidate TP-271 At ECCMID 2013 64
Dec 19, 2012: Cempra Announces Initiation Of Oral Solithromycin Global Phase III Clinical Trial In Patients With Community-acquired Bacterial Pneumonia 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Number of Products under Development for Community-Acquired Bacterial Pneumonia, H2 2014 8
Number of Products under Development for Community-Acquired Bacterial Pneumonia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Community-Acquired Bacterial Pneumonia - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 15
Community-Acquired Bacterial Pneumonia - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 16
Community-Acquired Bacterial Pneumonia - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H2 2014 17
Community-Acquired Bacterial Pneumonia - Pipeline by Melinta Therapeutics, Inc, H2 2014 18
Community-Acquired Bacterial Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2014 19
Community-Acquired Bacterial Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Community-Acquired Bacterial Pneumonia Therapeutics - Recent Pipeline Updates, H2 2014 45
Community-Acquired Bacterial Pneumonia - Dormant Projects, H2 2014 56
Community-Acquired Bacterial Pneumonia - Discontinued Products, H2 2014 57